Nektar Forms New Subsidiary in Anticipation of Opioid Medication Approval

With a potential approval of an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of a new subsidiary, Inheris Biopharma, Inc., which will be responsible for the launch and commercialization of the opioid. NKTR-181 is a novel, first-in-class, investigational opioid molecule developed for the treatment of chronic low back pain in adult patients new to opioid therapy.
Read more...

;